Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director | June 06, 2017 | June 13, 2017 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 06, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,921 |
Reported balance
After 2017-06-06 transaction · row 1
1 source rowRow 1 · 2017-06-06 · Exercise / conversion · Acquired 10,133 · Balance 18,921 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-06 · Exercise / conversion · Disposed 10,133 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,853 |
Reported balance
After 2017-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-07 · Grant · Acquired 15,853 · Balance 15,853 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
| Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2027-06-06 | Direct | 38,005 |
Reported balance
After 2017-06-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-07 · Grant · Acquired 38,005 · Balance 38,005 F3: Not applicable. F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.
F3: Not applicable.
F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
Jazz Pharmaceuticals plc
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 345,875 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 6,000 · Balance 345,875 F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2032-03-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 183,434 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 20:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 9,700 | $46.83 | $454,251.00 |
DisclosureSEC source: 0001765581-21-000122 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,700 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001765581-21-000120 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,932 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,598 | $129.87 | $856,902.71 |
DisclosureSEC source: 0001765581-21-000120 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,392 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 9,700 | $46.83 | $454,251.00 |
DisclosureSEC source: 0001765581-21-000120 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $131.58 | $65,790.00 |
DisclosureSEC source: 0001765581-21-000116 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,290 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,652 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001765581-21-000092 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,652 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2007 Equity Incentive Plan and vested over three years from the grant date, August 9, 2012, with 1/3 vesting on the first anniversary of the grant date and the remainder vested in 24 equal monthly installments thereafter. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 2,652 | $46.83 | $124,193.16 |
DisclosureSEC source: 0001765581-21-000092 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 250 | $170.00 | $42,500.00 |
DisclosureSEC source: 0001765581-21-000090 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,138 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $169.98 | $254,970.00 |
DisclosureSEC source: 0001765581-21-000090 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 10,850 | $180.67 | $1,960,269.50 |
DisclosureSEC source: 0001765581-21-000065 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,888 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,750 | $179.07 | $313,372.50 |
DisclosureSEC source: 0001765581-21-000059 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,738 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. Read SEC document |
| May 05, 2021 Filed May 5, 2021 23:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $170.00 | $85,000.00 |
DisclosureSEC source: 0001765581-21-000052 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,341 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 23:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $164.24 | $246,360.00 |
DisclosureSEC source: 0001765581-21-000052 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,841 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $164.96 | $247,440.00 |
DisclosureSEC source: 0001765581-21-000048 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,341 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 21,516 | $164.75 | $3,544,761.00 |
DisclosureSEC source: 0001765581-21-000034 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,841 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 9,600 | $170.00 | $1,632,000.00 |
DisclosureSEC source: 0001765581-21-000032 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,357 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 37,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000016 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,957 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 23:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 250 | $160.00 | $40,000.00 |
DisclosureSEC source: 0001765581-21-000006 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,032 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,250 | $156.15 | $195,187.50 |
DisclosureSEC source: 0001765581-21-000006 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,282 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 7,950 | $162.01 | $1,287,979.50 |
DisclosureSEC source: 0001765581-21-000004 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,532 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 03, 2020 Filed Dec 3, 2020 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 250 | $150.00 | $37,500.00 |
DisclosureSEC source: 0001765581-20-000123 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,482 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $140.58 | $140,580.00 |
DisclosureSEC source: 0001765581-20-000123 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,732 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 52 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,500 | $154.00 | $385,000.00 |
DisclosureSEC source: 0001765581-20-000101 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,680 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $145.13 | $145,130.00 |
DisclosureSEC source: 0001765581-20-000101 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,180 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 23:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,500 | $141.94 | $638,730.00 |
DisclosureSEC source: 0001765581-20-000099 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,180 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $134.90 | $67,450.00 |
DisclosureSEC source: 0001765581-20-000095 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,680 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $130.00 | $390,000.00 |
DisclosureSEC source: 0001765581-20-000093 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,180 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 23:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 15,071 | $124.50 | $1,876,339.50 |
DisclosureSEC source: 0001765581-20-000032 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,033 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 129,115 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000018 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,115 Underlying: Ordinary Shares · 129,115 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 885 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000018 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885 Underlying: Ordinary Shares · 885 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000018 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,104 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,679 | $127.25 | $340,902.75 |
DisclosureSEC source: 0001765581-20-000014 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,104 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 6,895 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001765581-20-000014 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,895 shares Expires 2020-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of March 8, 2010, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 8, 2014. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 6,895 | $11.48 | $79,154.60 |
DisclosureSEC source: 0001765581-20-000014 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $143.83 | $143,830.00 |
DisclosureSEC source: 0001765581-20-000008 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,888 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 250 | $150.00 | $37,500.00 |
DisclosureSEC source: 0001765581-20-000002 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,888 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $149.51 | $149,510.00 |
DisclosureSEC source: 0001765581-20-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,138 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 10,750 | $150.00 | $1,612,500.00 |
DisclosureSEC source: 0001765581-19-000096 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,138 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 33 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2019. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 23:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $130.00 | $65,000.00 |
DisclosureSEC source: 0001765581-19-000092 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,855 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $130.00 | $65,000.00 |
DisclosureSEC source: 0001765581-19-000088 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,355 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,288 | $135.82 | $582,396.16 |
DisclosureSEC source: 0001765581-19-000033 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,715 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,586 | $135.82 | $622,870.52 |
DisclosureSEC source: 0001765581-19-000033 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,003 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 124,286 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000017 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,286 Underlying: Ordinary Shares · 124,286 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 714 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000017 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Underlying: Ordinary Shares · 714 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000017 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,589 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,420 | $127.76 | $436,939.20 |
DisclosureSEC source: 0001765581-19-000004 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,589 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,679 | $126.25 | $338,223.75 |
DisclosureSEC source: 0001765581-19-000004 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,009 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $151.78 | $151,780.00 |
DisclosureSEC source: 0001232524-18-000200 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,688 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 73 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 23:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,300 | $159.45 | $207,289.94 |
DisclosureSEC source: 0001232524-18-000185 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,615 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.29 to $160.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,300 | $167.99 | $218,387.00 |
DisclosureSEC source: 0001232524-18-000176 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,915 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.